Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy
Tuesday, June 6, 2017 - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to tafamidis, the company ’s investigational treatment for transthyretin cardiomyopathy (TTR-CM). This...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Cardiomyopathy | Drugs & Pharmacology | Food and Drug Administration (FDA) | Heart | New Drug Applications | Pfizer